gsk is pushing relenza, page-5

Gonewest,
instead of posting catchcries like portable loos, why not provide facts. Only fools cannot see Peter Cook and GSK are the greatest drag on BTA.

In a strong Northern seasonal flu the recent first half results speak for itself:

1)“Royalty income from sales of Relenza was $3,819 (2007: $16,483)”.DOWN 77%
2)“Collaboration income was $6,657 (2007: $9,560)” DOWN 30.4%
“Milestone payments of $NIL (2007: $3,419)” down 100% DESPITE R&D + Product development expenses increasing 17% from $10.584m to $12.361m. INCREASED EXPENSE = NO MILESTONE ACHIEVED = INCREASED EXECUTIVE REMUNERATIONS!!!
3) ”The underlying business booked a net loss of $12.8 million for the half versus net profit of $5.5 million previously”.

The Good news is one parasite had left the board.

LOL